About Collegium Pharma
Collegium Pharma is a company based in Canton (United States) founded in 2002 by Michael Heffernan. Collegium Pharma has raised $103 million across 8 funding rounds from investors including TPG, HHS and RA Capital. The company has 357 employees. Collegium Pharma has completed 2 acquisitions, including BioDelivery Sciences International and Ironshore Pharmaceuticals. Collegium Pharma offers products and services including Differentiated Medications. Collegium Pharma operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Canton, United States
- Employees 357
- Founders Michael Heffernan
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website collegiumpharma.com
- Social LinkedIn X
- Legal Name Collegium Pharmaceutical, Inc.
- Annual Revenue$780.57 M (USD)23.62as on Dec 31, 2025
- Net Profit$62.87 M (USD)-9.13as on Dec 31, 2025
- EBITDA$413.16 M (USD)14.62as on Dec 31, 2025
- Total Equity Funding$103M (USD)
in 8 rounds
- Latest Funding Round$20M (USD), Post-IPO
Nov 2018
- InvestorsTPG
& 9 more
- Employee Count357
- Investments & AcquisitionsBioDelivery Sciences International
& 1 more
Products & Services of Collegium Pharma
Collegium Pharma offers a comprehensive portfolio of products and services, including Differentiated Medications.
Medications addressing serious medical conditions through scientific innovation.
Funding Insights of Collegium Pharma
Collegium Pharma has successfully raised a total of $103M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103M
- Total Rounds 8
- Last Round Post-IPO — $20M
- First Round $5.5M
(Nov 2006)
- Investors Count 10
All 8 funding rounds of Collegium Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $20M | Post-IPO | – | – | – |
| Mar 2015 | $50M | Series C | – | – | |
| Sep 2014 | $472,811 | Grant | – | – | |
| Oct 2013 | $4M | Series B | – | – | – |
| Feb 2012 | $22.5M | Series B | – | Longitude Capital, Skyline Ventures | |
| Mar 2010 | $1M | Series B | – | – | – |
| Jul 2008 | $20M | Series B | – | – | |
| Nov 2006 | $5.5M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Collegium Pharma
Collegium Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Private equity firm focused on life science sector | – | longitudecapital.com | Menlo Park, United States | |
US life sciences companies are invested in by Skyline Ventures. | – | skylineventures.com | Palo Alto, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
US-focused private equity and venture capital investments are managed. | – | bostonmillenniapartners.com | Boston, United States | |
- | – | ecor1cap.com | - | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Diversified investment management services are provided by Westfield Capital. | 1989 | westfieldcapital.com | Boston, United States |
Investor details for Collegium Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Collegium Pharma
45 people are tracked at Collegium Pharma (24 in leadership, 6 in board & advisors, 15 in team); the tracked headcount is 357.
| Name | Role | Group |
|---|---|---|
Michael Heffernan | Founder &CEO | Leadership |
Joe Ciaffoni | CEO | Leadership |
Mary Lawrence | Director National Accounts | Leadership |
Tim Pergram | Senior Director, National Accounts | Leadership |
Frank Bagnato | Senior Director Sales | Leadership |
Scott Dreyer | Chief Commercial Officer | Leadership |
Arun Padmanabhan | Vice President, Pain Sales & Marketing, And Commercial Training & Development | Leadership |
Sean Spears | Vice President Marketing | Leadership |
Kristi Paquette | Vp, Market Access & Trade | Leadership |
Sara Yin | Senior Director, Market Access Strategy & Operations | Leadership |
Ravi K. Varanasi | Senior Director, Commercial Manufacturing & CMC | Leadership |
Ron Weiss | Vice President, Commercial Operations | Leadership |
Nick Zweig | Director HR Talent Acquisition | Leadership |
Brianne Meehan | Director, Talent Management And Development And HR Business Partner | Leadership |
Kelly Clements | Chief People Officer | Leadership |
Melinda O'Connor | Vice President, Clinical Operations | Leadership |
Darby J. Flaherty | Director, Information Technology And Security | Leadership |
Donna Gerace (Kalogianis) | Director, Data Warehouse & Reporting | Leadership |
Sonal Bhandary | Head Of IT And Digital Operations | Leadership |
Joy Rasmussen | Vice President Of Sales | Leadership |
25 more people are available in the full profile.
Complete people profiles for Collegium Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Collegium Pharma
Collegium Pharma is a publicly listed company on the NASDAQ with ticker symbol COLL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 May 2015
- Listed onNASDAQ: COLL
- Listed entityCollegium Pharmaceutical, Inc.
- Exchange sectorHealth technology
- ISINUS19459J1043
- Share price$22.11 (+0.82% on the day) · 2026-10-08
- Market capitalisation$719.8M
- Price to earnings17.9
- EPS (diluted, trailing year)$1.23
- Volume (last session)532,922
Financials of Collegium Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $780.6M | $62.9M | $413.2M |
| 2024 | $631.5M | $69.2M | $360.5M |
| 2023 | $566.8M | $48.2M | $324.7M |
| 2022 | $463.9M | -$25.0M | $203.8M |
| 2021 | $276.9M | $71.5M | $94.1M |
Detailed financial statements for Collegium Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Collegium Pharma
Collegium Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioDelivery Sciences International and Ironshore Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drug delivery technology and ADHD therapeutics are developed. | ironshorepharma.com | George Town, Cayman Islands | 2008 | Jul 2024 | $525M | |
Specialty pharmaceutical solutions are developed for pain management and addiction. | bdsi.com | Raleigh, United States | 1997 | Feb 2022 | •••• |
Complete acquisition details for Collegium Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Collegium Pharma
6 dated milestones of Collegium Pharma across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Collegium Pharma is founded.
- Funding First funding round of $5.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
- Acquisition Acquires BioDelivery Sciences International.
- Acquisition Acquires Ironshore Pharmaceuticals.
Competitors of Collegium Pharma
Collegium Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. | |
| herontx.com | 1983 | Redwood, United States | $32.14M | 21 | Reformulated injectables for chemotherapy side effects and pain are developed. | |
| painreform.com | 2007 | Herzliya, Israel | $12M | – | Pain treatment products are developed through reformulation technologies. | |
| trevena.com | 2007 | Philadelphia, United States | $203M | 35 | GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | |
| satsumarx.com | 2016 | San Francisco, United States | $74.13M | 24 | Therapeutics for migraine treatment are developed using nasal delivery. | |
| concentricanalgesics.com | 2014 | San Francisco, United States | $85.46M | – | Developer of platform for developing pro-drugs |
Detailed competitors of Collegium Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Collegium Pharma
The website of Collegium Pharma (collegiumpharma.com) receives about 13.5K visits a month and ranks #1,457,207 among all websites worldwide, #1,903 in Biotechnology and Pharmaceuticals.
- Monthly visits13.5K
▼ 26.7% vs previous month
- Unique visitors9.5K
per month
- Global rank#1,457,207
among all websites
- Category rank#1,903
Health · Biotechnology and Pharmaceuticals
- Bounce rate67%
- Pages per visit1.7
- Average visit1 min 00 sec
- DevicesDesktop 19% · Mobile 81%
Websites whose visitors overlap most with Collegium Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| prosidion.com | 100% | – | – | View details | |
| biotrondiagnostics.com | 100% | 1.5K | #9,362,675 | View details | |
| bionovo.com | 100% | – | – | View details | |
| taigenbiotech.com | 100% | 1.8K | #8,037,594 | View details | |
phytopharm.com | phytopharm.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Collegium Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Collegium Pharma
Complete news archive for Collegium Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Collegium Pharma
10 companies that operate in the same segment as Collegium Pharma (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Developer of drugs for rare and orphan disease conditions | 2014 | Minneapolis, Minnesota, United States | USD 16.29 M | – | 14 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Collegium Pharma
Collegium Pharma was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Collegium Pharma is headquartered in Canton, United States. It is registered at Canton, Ohio, United States.
Michael Heffernan is the current CEO of Collegium Pharma. They have also founded this company.
Collegium Pharma is a funded company, having raised a total of $103M across 8 funding rounds to date. The company's 1st funding round was a Series A of $5.5M, raised on Nov 2006.
Collegium Pharma has 357 employees.
Annual revenue of Collegium Pharma is $780.57M as on Dec 31, 2025.
Therapeutics for chronic pain management are developed by Collegium Pharmaceutical, which was founded in 2002 and is based in Canton, United States. The proprietary DETERx platform is used to combine active ingredients with fatty acids and waxes, forming microsphere capsules with extended-release and abuse-deterrent features. Xtampza ER serves as the flagship product, delivering extended-release oxycodone. Formulations for oxymorphone, hydrocodone, morphine, and methylphenidate are also produced.
Collegium Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Collegium Pharma offers Differentiated Medications.
Yes, Collegium Pharma is publicly traded on NASDAQ under the ticker symbol COLL.
Collegium Pharma has made 2 acquisitions, including BioDelivery Sciences International, and Ironshore Pharmaceuticals.
Collegium Pharma has 10 investors. Key investors include TPG, HHS, RA Capital, Frazier Healthcare Partners, and Westfield Capital.